2 active not recruiting, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Chronic Myelogenous Leukemia - Chronic Phase: new trials by email Literature Review of Chronic Myelogenous Leukemia - Chronic Phase trials Research Report on Chronic Myelogenous Leukemia - Chronic Phase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia asciminib - Chronic Myelogenous Leukemia - Chronic Phase | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 34 | 2022-11-11 | 2025-10-14 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Nilotinib - Chronic Myelogenous Leukemia - Chronic Phase | Phase 2 | Terminated | Novartis Pharmaceuticals | 18 | 2008-10-01 | 2021-08-18 |
Leukemia, Myeloid, Chronic-Phase (3) · Blast Crisis (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1)
Bone Marrow Diseases (3) · Chronic Disease (3) · Disease Attributes (3) · Hemic and Lymphatic Diseases (3) · Leukemia, Myeloid (3) · Myeloproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Carcinogenesis (1) · Cell Transformation, Neoplastic (1)
Blood Specimen Collection (1) · Cyclophosphamide (1) · Cyclosporine (1) · Methotrexate (1) · Mycophenolic Acid (1) · Tacrolimus (1) · Vorinostat (1) · asciminib (1) · nilotinib (1)
Novartis Pharmaceuticals (2) · University of Michigan Rogel Cancer Center (1)
United States (3)
PMID 28042454, PMID 39387441, PMID 42784255
UL1TR002240 (1)